May 29, 2019
1 min read
Save

Dextenza receives C-code, pass-through payment status

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The CMS approved transitional pass-through payment status and established a new reimbursement code for Dextenza.

The code, C9048, will become effective July 1, according to a press release from Ocular Therapeutix.

The C-code facilitates the reimbursement of Dextenza (dexamethasone ophthalmic insert) until a J-code is approved and becomes effective. Ocular Therapeutix announced earlier this month that the CMS had included Dextenza on its list of products preliminarily recommended for a new dedicated Healthcare Common Procedure Coding System J-code, which would become effective Jan. 1, 2020, if approved.